ACC.24 - A structured approach to treat hypercholesterolemia with an "inclisiran first" strategy in US patients with ASCVD performs much better than usual care, according to Michael Koren. He hopes that the results of VICTORION-INITIATE are a wake-up call to treat patients more aggressively with lipid-lowering therapies.
Aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
Be part of the knowledge.™Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
Choose a format
Media formats available:
Facebook Comments